Treatment of nonpsychotic relatives of patients with schizophrenia: Six case studies
β Scribed by Tsuang, Ming T. ;Stone, William S. ;Tarbox, Sarah I. ;Faraone, Stephen V.
- Publisher
- John Wiley and Sons
- Year
- 2002
- Tongue
- English
- Weight
- 67 KB
- Volume
- 114
- Category
- Article
- ISSN
- 0148-7299
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
## Abstract ## Objective To explore the relative association of adverse events with healthβrelated quality of life (HRQL) in patients (__N__β=β16β091) with schizophrenia, treated with antipsychotic medication. ## Methods In this __post hoc__ analysis of data from two 3βyear observational studies
Background Following an earlier study in which elderly patients with schizophrenia had their typical antipsychotic medication changed to olanzapine or risperidone, the 61 patients were followed for up to a further six months to see if either treatment was superior in terms of efficacy or side effect
Ziprasidone is a novel antipsychotic which, in oral formulation, has been shown to be effective and well tolerated in the treatment of acute psychosis. This pilot study examined the efficacy and tolerability of the intramuscular (IM) formulation and the transition from IM to oral ziprasidone in pati
## Abstract Lymphoid neoplasms (LNs), including nonβHodgkin's lymphoma (NHL), Hodgkin's lymphoma (HL), lymphoproliferative syndrome (LPS) and multiple myeloma (MM), are among the most frequent cancers (βΌ17,000 new cases per year in France), after those related to smoking. LNs were investigated usin
## Abstract Negative symptoms are considered the most debilitating and refractory aspect of schizophrenia, being associated with poor social, occupational and global outcomes. Conventional antipsychotics have limited efficacy against these symptoms and poor tolerability profiles. Atypical antipsych